Antitumor activity of delimotecan against human metastatic melanoma: Pharmacokinetics and molecular determinants

International Journal of Cancer

Volumn 125, Issue 10, 2009, Pages 2456-2464

  Bigioni, Mario ^a   Parlani, Massimo ^a   Bressan, Alessandro ^a   Bellarosa, Daniela ^a   Rivoltini, Licia ^b   Animati, Fabio ^a   Crea, Attilio ^a   Bugianesi, Rossana ^a   Maggi, Carlo Alberto ^a   Manzini, Stefano ^a   Binaschi, Monica ^a  

^a Menarini Ricerche SpA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cathepsin B; Delimotecan; Macrophages; Metastatic melanoma

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; DELIMOTECAN; DRUG METABOLITE; MESSENGER RNA; T 0055; T 2513; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER; MACROPHAGE; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; DEXTRANS; FEMALE; HUMANS; LEUKEMIA, MYELOID; MACROPHAGES; MELANOMA; MICE; MICE, NUDE; OVARIAN NEOPLASMS; TISSUE DISTRIBUTION; TOPOTECAN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349850469     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24661     Document Type: Article

References (23)

1. Hersey P. Advances in the non-surgical treatment of melanoma. Expert Opin Investig Drugs 2002;11:75-85.
2. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007;12:1114-1123 (Pubitemid 350007023)
3. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999;9:51-58 (Pubitemid 29169989)
4. Soengas MS Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene 2003;22:3138-3151
5. Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 2003;12:2205-2211 (Pubitemid 37541234)
6. Garcia-Carbonero R Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-661
7. Okuno S, Harada M, Yano T, Yano S, Kiuchi S, Tsuda N, Sakamura Y, Imai J, Kawaguchi T, Tsujihara K. Complete regression of xenografted human carcinoma by camptothecin analogue-carboxymethyldextran conjugate (T-0128). Cancer Res 2000;60:2988-2995 (Pubitemid 30395825)
8. Veltkamp SA, Witteveen EO, Capriati A, Crea A, Animati F, Voogel-Fuchs M, Van den Heuvel Ingeborg JGM, Beijnen JH, Voest EE Schellens JHM. Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. Clin Cancer Res 2008;14:7535-7544
9. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;98:335-344 (Pubitemid 43338213)
10. Harada M, Imai J, Okuno S, Suzuki T. Macrophage-mediated activation of camptothecin analogue T2513-carboxymethyl dextran conjugate (T-0128): possible cellular mechanism for antitumor activity. J Control Release 2000;69:389-397 (Pubitemid 30845483)
11. Binaschi M, Parlani M, Bellarosa D, Bigioni M, Salvatore C, Palma C, Crea A, Maggi CA, Manzini S, Goso C. Human and murine macrophages mediate activation of MEN4901/T-0128, a new promising camptothecin analogue-polysaccharide conjugate. Anticancer Drugs 2006;17:1119-1126 (Pubitemid 44673393)
12. Mohamed MM Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nature Reviews Cancer 2006;6:764-775
13. Lugini L, Lozupone F, Matarrese P, Funaro C, Luciani F, Malorni W, Rivoltini L, Castelli C, Tinari A, Piris A, Parmiani G, Fais S. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab Invest 2003;83:1555-1567 (Pubitemid 37424017)
14. Lozupone F, Pende D, Burgio VL, Castelli C, Spada M, Venditti M, Luciani F, Lugini L, Federici C, Ramoni C, Rivoltini L, Parmiani G, et al. Effect of human natural killer and γδ T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res 2004;64:378-385
15. Page B, Page M, Noel C. A new fluorimetric assay for cytotoxicity measurements in vitro. Int J Oncol 1993;3:473-476 (Pubitemid 23271916)
16. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 1998;77:1-10.
17. Geran RI, Greenberg NH, Mac Donald MM, Schumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Reports 1972;3:1-88.
18. Teicher BA. Anticancer drug development guide. Totowa, New Jersey: Humana Press, 1997.
19. Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, Iessi E, Gentile M, Luciani F, Parmiani G, Rivoltini L, Malorni W, Fais S. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006;66:3629-3638
20. Fujita F, Koike M, Fujita M, Sakamoto Y, Okuno S, Takayuki Kawaguchi T, Yano S, Yano T, Kiuchi S, Fujiwara T, Kudoh S, Kakushima M. MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice. Clin Cancer Res 2005;11:1650-1657 (Pubitemid 40315250)
21. Pollard JW. Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer 2004;4:71-78 (Pubitemid 38082155)
22. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue X, Pollard JW. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-11246 (Pubitemid 46009952)
23. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-555 (Pubitemid 35223554)